<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">World Allergy Organ J</journal-id><journal-id journal-id-type="iso-abbrev">World Allergy Organ J</journal-id><journal-title-group><journal-title>The World Allergy Organization Journal</journal-title></journal-title-group><issn pub-type="epub">1939-4551</issn><publisher><publisher-name>World Allergy Organization</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3643393</article-id><article-id pub-id-type="publisher-id">1939-4551-6-S1-P117</article-id><article-id pub-id-type="doi">10.1186/1939-4551-6-S1-P117</article-id><article-categories><subj-group subj-group-type="heading"><subject>Meeting Abstract</subject></subj-group></article-categories><title-group><article-title>Allergic diseases of the skin and drug allergies &#x02013; 2031. Effectiveness of autologous serum therapy in patients of chronic urticaria: a randomized, single-blind, controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Debbarman</surname><given-names>Panchami</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>Department of Dermatology, Medical College, Kolkata, Kolkata, India</aff><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>23</day><month>4</month><year>2013</year></pub-date><volume>6</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">2nd WAO International Scientific Conference (WISC 2012), Abstracts</named-content><named-content content-type="supplement-editor">Ruby Pawankar, Lanny J Rosenwasser and Stephen T Holgate</named-content></supplement><fpage>P117</fpage><lpage>P117</lpage><permissions><copyright-statement>Copyright &#x000a9;2013 Debbarman; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Debbarman; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.waojournal.org/content/6/S1/P117"/><conference><conf-date>6-9 December 2012</conf-date><conf-name>2nd WAO International Scientific Conference (WISC 2012)</conf-name><conf-loc>Hyderabad, India</conf-loc></conference></article-meta></front><body><sec><title>Background</title><p>Chronic urticaria (CU) is a vexing problem to clinicians and patients alike. Search for newer modalities which can reduce pill burden is a felt need. The scope of Autologous serum therapy (AST) thus needs evaluation.</p></sec><sec sec-type="methods"><title>Methods</title><p>Patient blind, parallel group, randomised, controlled study of two study arm. 54 patients were given AST (GroupA) and control group of 57 patients given injection normal saline (placebo) (GroupB). AST/Placebo was given every week for 9 weeks and then followed-up for another 3 weeks. Levocetrizine was advised to be taken SOS in both groups. AU was diagnosed by autologous serum skin test. Urticaria total severity score (TSS) and Bengali version of Dermatologic life quality index (DLQI) was used as primary efficacy variable. Mann-Whitney U test and Freidman&#x02019;s ANOVA followed by post hoc Dunn&#x02019;s test was used for analysis.</p></sec><sec sec-type="results"><title>Results</title><p>TSS was comparable (p&#x0003e;0.05) at baseline in Group A (17.74&#x000b1;0.44) and Group B (17.31&#x000b1;0.66). TSS showed significant improvement (p&#x0003c;0.001) from baseline 7<sup>th</sup> week (12.56&#x000b1;2.24) onwards in group A and 8<sup>th</sup> week (13.29&#x000b1;1.80) onwards in group B which continued till end-of-treatment visit. Between group comparison showed significant improvement (p&#x0003c;0.001) 4<sup>th</sup> week onwards which persisted till 12<sup>th</sup> week. DLQI showed significant improvement (p=0.006) in Group A than Group B at the end of study. Both AU and non-AU patients showed comparable (p&#x0003e;0.05) improvement of TSS.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>AST shows promise in treatment of urticaria regardless of the autoimmune nature.</p></sec></body></article>